Introduction {#S1}
============

Frontotemporal dementia syndromes are a common cause of early onset (\<65 years of age) dementia ([@B1]). These syndromes are characterized by dramatic changes in personality, language, behavior, and social conduct. The most prevalent syndrome is behavioral variant frontotemporal dementia (bvFTD) ([@B2]); less prevalent are a number of primary progressive aphasias ([@B3]). bvFTD patients are commonly misdiagnosed as Alzheimer's disease (AD) because of overlap in clinical presentations, although the regions of the brain affected and the types of underlying cellular pathologies differ in the two disorders. Recent advances in the genetics of frontotemporal dementia syndromes have identified aberration in three key genes, *C9ORF72* ([@B4], [@B5]), *progranulin* ([@B6]), and *tau* ([@B7]). A genetic biomarker for the *C9ORF72* gene expansion has been developed, and genetic screening of bvFTD for this expansion is now commonly performed at an early stage of diagnosis. Increasing effort is being made to develop blood biomarkers based on gene products of *progranulin* and *tau* with the aim of differentiating the underlying brain proteinopathies in bvFTD, as well as for target validation in clinical trials ([@B8], [@B9]).

One aspect of the neuropathology of bvFTD that has not been exploited in the development of selective biomarkers are the changes in lipids. In contrast to AD, there is considerable early loss of significant amounts of brain tissue in all frontotemporal dementia syndromes with concomitant loss of lipids ([@B10]--[@B13]). Lipids are a major constituent of brain tissue, making up 39.6% of gray matter and 64.6% of white matter ([@B14]). Another aspect of the neuropathology of bvFTD that contributes toward altered lipid status is the behavioral changes that impact on diet and eating behaviors. Key features of bvFTD are excessive or binge eating, increased consumption of sweet foods (sugar) and alcohol, and increased body mass index (BMI) ([@B15]--[@B17]). In a recent study, blood lipid analyses showed increased levels of triglyceride (TG) and decreased levels of HDL-cholesterol in a cohort of bvFTD compared to controls, indicative of lipid metabolic abnormality ([@B18]). Apart from total TG and total cholesterol, no other lipids have been measured in these syndromes; no individual lipid species have been measured.

Here, we undertook a comprehensive analysis of global plasma lipid levels in bvFTD compared with AD and controls using untargeted lipidomics technology. Lipidomics, based on HPLC and mass spectrometry, allows detection and quantification of individual molecular species of a broad range of lipids. It has been extensively used in biomedical research and has provided invaluable data in understanding the pathogenesis of a number of diseases. Lipidomics has also provided the scope for use in disease classification and biomarker development. Thus far, no lipidomics analysis has been reported for bvFTD. The primary aim of our study was to generate profiles of lipids present in blood plasma from patients with bvFTD and to determine any changes compared to patients with AD and controls without neurological or psychiatric disorders. The secondary aim was to identify individual lipid species that could be used in follow-up studies to develop potential biomarkers to objectively distinguish bvFTD patients from AD patients and controls.

Materials and Methods {#S2}
=====================

Chemicals and Materials {#S2-1}
-----------------------

Lipids were extracted using chloroform, methanol, and isopropanol (Sigma Aldrich, St. Louis, MO, USA) and ultrapure water (Millipore). All solvents used were HPLC grade or higher. Glass pipettes and tubes were used wherever possible, and the use of plasticware was minimized during lipid extraction to avoid contamination of samples. Glass tubes and glass transfer pipettes were purchased from Sigma and vWR. Lipid internal standards (ISTDs) were purchased from Avanti Polar Lipids Inc. (Alabaster, AL, USA). These include phosphatidylcholine (PC, 19:0), sphingomyelin (SM, 12:0), phosphatidylethanolamine (PE, 17:0), phosphatidylglycerol (PG, 17:0), phosphatidylserine (PS, 17:0), phosphatidic acid (PA, 17:0), ceramide (Cer, d18:1, 12:0), diglyceride (DG, 1,3 18:0 d5), cholesteryl ester (ChE, 19:0), monoglyceride (MG, 17:0), TG mix d5 (Avanti Code LM-6000), DG mix d5 (Avanti Code LM-6001), phosphatidylinositol (PI, 17:0 14:1), C12 GluCer, C12 sulfatide, C17 Cer, C17 sphingosine (So), C17 S1P, C12 C1P, D3 C20 fatty acid, and C12 LacCer. Lipid ISTDs were prepared as a mixture at 10 pmol/μl in methyl-tert butyl ether and methanol (MTBE:methanol, 1:1 v/v).

Patient Blood Collection {#S2-2}
------------------------

Patients with bvFTD (M/F, 11/5), patients with AD (M/F, 8/6) and healthy controls (M/F, 8/14) were included in the study. The mean age of these three groups were 65.0 ± 6.5, 70.9 ± 5.7, and 73.7 ± 5.4 years, respectively. They were recruited from FRONTIER, the frontotemporal dementia clinical research group at Neuroscience Research Australia, Sydney. All patients underwent a comprehensive neurologic and cognitive assessment and their clinical status established as previously described ([@B18]), and they met their respective current clinical diagnostic criteria ([@B16], [@B19]). The controls were recruited from a panel of healthy study volunteers ([@B18]) and had no neurological (i.e., no evidence of cognitive impairment) or psychiatric disorders or family histories of such disorders. Fasted blood was collected, and plasma was prepared by centrifugation at 3,500 rpm for 10 min at 4°C, which was then aliquoted and stored at −80°C until use. This study was approved by the University of New South Wales human ethics committee (approval number: HC12573), and the blood was obtained following written informed consent from the participant and/or primary carer.

Lipid Extraction {#S2-3}
----------------

Plasma was thawed on ice prior to extraction. An aliquot of 80 µl of plasma was mixed with 10 µl of the internal standard in a glass tube. Lipid extraction was based on the method by Bligh and Dyer ([@B20]). Briefly, methanol (600 µl), chloroform (1,000 µl), and ultrapure water (500 µl) were added sequentially and vortexed each time. Samples were then centrifuged at 3,000 rpm for 25 min at room temperature. The lower (solvent) phase was collected and transferred into a new glass tube using a glass Pasteur pipette. Chloroform (600 µl) was added, vortexed, and centrifuged at 3,000 rpm for 25 min. The lower phase was collected and transferred into a new glass tube and dried under nitrogen gas. The dried lipid samples were reconstituted in 100 µl of isopropanol/methanol (1:1).

LC-MS/MS Protocol {#S2-4}
-----------------

Lipid extract (10 µl) was analyzed using a Q-Exactive Plus Mass Spectrometer coupled to a U3000 UPLC system (ThermoFisher Scientific). Chromatography was performed at 60°C on a Waters CSH C18 UHPLC column 2.1 × 100 mm, 1.8 µM with VanGuard guard column.

Solvent A was 6:4 acetonitrile:water and Solvent B was 1:9 acetonitrile:isopropanol, both with 10 mM ammonium formate and 0.1% formic acid. Lipids were chromatographed according to the method of Castro-Perez et al ([@B21]). Briefly, a 30-min gradient running from 30 to 100% of solvent B was performed, eluting lipids in order of hydrophobicity. Column eluate was directed into the electrospray ionization (ESI) source of the mass spectrometer where a HESI probe was employed. Source parameters were broadly optimized on a range of lipid standards prior to the analysis. The mass spectrometer was run in data-dependent acquisition mode. A survey scan over the mass range 200--1,200 at resolution 70 K was followed by 10 data dependent MS/MS scans on the most intense ions in the survey at 15 K resolution. Dynamic exclusion was used to improve the number of ions targeted. Cycle time was approximately 1 s. Samples were run in both positive and negative polarities. The samples were run in a random order (generated using Microsoft Excel). This is important to avoid batch effects/changing instrument performance effects. Data were analyzed in LipidSearch software 4.1.16. Data were searched against the standard Lipidsearch database with all common mammalian lipid classes included. The search results were then grouped according to sample type and aligned for differential analysis. Aligned data (containing lipid identity, retention time, peak area, etc.) were exported to Excel software. Relative abundance of lipids was obtained from peak areas normalized to ISTDs. Individual species that were significantly altered in bvFTD and AD compared to control were presented as fold changes on linear scale. Fold changes were calculated by dividing disease abundance by control abundance and then subtracting by 1; zero, therefore, represents no change. Increased species are represented by red symbols above the zero line (e.g., 0.5 = 50% increase) and decreased species are represented by blue symbols below the zero line (e.g., −0.5 = 50% decrease).

Statistics {#S2-5}
----------

Statistical analyses were performed using SPSS Statistics software (IBM, Chicago, IL, USA). Multivariate analyses (general linear model) covarying for age and gender were used to determine differences in lipid levels in the control, bvFTD, and AD clinical groups with *post hoc* statistical significance set at *p* \< 0.05. Pearson correlations were used to determine if changes in the level of a lipid were associated with all other lipids with statistical significance set at *p* \< 0.05.

Results {#S3}
=======

A Global Analysis of bvFTD Plasma Lipids {#S3-1}
----------------------------------------

Behavioral variant frontotemporal dementia is characterized by brain atrophy and concomitant loss of lipids. bvFTD is further characterized by eating abnormalities and changes to BMI and metabolism. However, very little is known about changes in the level and distribution of blood lipids in bvFTD. Here, we undertook a comprehensive lipidomics analysis of blood plasma from patients with bvFTD, AD, and controls without dementia with the potential aim of developing lipid biomarkers for bvFTD. We measured all major classes of lipids using liquid chromatography-tandem mass spectrometry. The total relative abundance (normalized to ISTDs) of each lipid class in each cohort is shown in Table [1](#T1){ref-type="table"}. Changes to lipid levels in bvFTD and AD were analyzed using a single statistical approach---multivariate tests covarying for age and gender, and each lipid class is described in detail below. Both age (*p* = 0.368) and gender (*p* = 0.176) had no significant effect on lipid levels. The number of species identified in each lipid class is also shown in Table [1](#T1){ref-type="table"} and described in detail below. We also identified individual lipid species that could potentially be used for developing biomarkers for bvFTD that differentiate them from both AD patients and controls, and these are also described in detail below.

###### 

Total relative abundance and number of species identified for each lipid class.

  Lipid                          Symbol   Species   Total abundance   SE               Significance                                                                           
  ------------------------------ -------- --------- ----------------- ---------------- ---------------- --------------- --------------- --------------- ---------- ---------- ----------
  **Glycerolipids**                                                                                                                                                           
  Triglyceride                   TG       1,115     28,288,797,070    37,809,429,330   35,132,579,390   2,315,247,310   2,834,542,577   2,651,164,228   0.0215\*   0.0565     0.4973
  Diglyceride                    DG       282       798,173,211       1,150,203,620    1,088,099,179    115,173,752     141,006,493     131,884,197     0.0835     0.1025     0.7511
  Monoglyceride                  MG       22        15,367,133        19,978,654       17,477,209       1,851,801       2,267,148       2,120,477       0.1563     0.4547     0.4282
                                                                                                                                                                              
  **Phospholipids**                                                                                                                                                           
  Phosphatidylcholine            PC       1,062     68,308,624,220    61,637,766,990   68,242,851,540   2,241,151,424   2,743,827,454   2,566,317,844   0.0916     0.9846     0.0878
  Phosphatidylserine             PS       91        1,713,312,131     1,360,454,204    1,747,110,899    81,147,600      99,348,491      92,921,224      0.0154\*   0.7841     0.0070\*
  phosphatidylethanolamine       PE       152       1,690,377,391     1,604,351,098    1,816,156,828    93,113,124      113,997,806     106,622,814     0.5955     0.3760     0.1848
  Phosphatidylinositol           PI       29        110,809,533       85,315,521       115,238,810      10,804,479      13,227,855      12,372,090      0.1787     0.7874     0.1080
  Phosphatidylglycerol           PG       21        352,956,480       188,169,159      272,377,988      41,974,952      51,389,667      48,065,055      0.0278\*   0.2103     0.2412
  Phosphatidic acid              PA       6         276,188,531       245,437,646      277,454,089      14,785,570      18,101,879      16,930,793      0.2349     0.9551     0.2065
                                                                                                                                                                              
  **Sphingolipids**                                                                                                                                                           
  Ceramide                       Cer      59        700,586,282       627,391,708      711,568,776      54,061,427      66,187,062      61,905,145      0.4374     0.8937     0.3617
  Monoglycosylceramide           CerG1    34        306,532,770       296,609,130      303,378,080      25,956,537      31,778,423      29,722,545      0.8259     0.9363     0.8780
  Ceramide phosphate             CerP     2         705,982           689,733          763,499          166,052         203,297         190,145         0.9551     0.8197     0.7938
  Sphingomyelin                  SM       229       17,238,766,380    16,558,095,510   18,595,049,360   828,842,335     1,014,746,407   949,098,241     0.6369     0.2845     0.1526
  Sphingosine                    So       3         36,750,547        32,289,386       39,606,196       2,424,937       2,968,835       2,776,768       0.2926     0.4398     0.0807
  Sphingosine phosphate          Sop      2         561,125           420,566          537,341          91,932          112,551         105,270         0.3809     0.8648     0.4561
                                                                                                                                                                              
  **Sterols**                                                                                                                                                                 
  Cholesteryl ester              ChE      44        2,036,113,428     1,720,063,142    1,851,966,097    104,534,543     127,980,977     119,701,356     0.0868     0.2497     0.4591
  Zymosteryl ester               ZyE      22        945,498,557       832,938,261      862,188,966      45,898,483      56,193,222      52,557,848      0.0868     0.2497     0.4591
                                                                                                                                                                              
  **Dietary lipids**                                                                                                                                                          
  Monogalactosyldiacylglycerol   MGDG     12        461,200,788       391,370,141      485,257,104      18,164,178      22,238,288      20,799,601      0.0310\*   0.3854     0.0037\*
  Stigmasteryl ester             StE      3         505,584,209       465,560,451      449,560,609      29,211,953      35,764,008      33,450,286      0.4320     0.2107     0.7473
  Sitosteryl ester               SiE      7         42,637,336        28,208,118       34,262,783       2,733,091       3,346,106       3,129,632       0.0037\*   0.0483\*   0.1964
  Wax ester                      WE       28        902,221,864       789,333,910      800,780,727      37,356,450      45,735,264      42,776,459      0.0870     0.0788     0.8569

*Multivariate analyses covarying for age and gender were used to determine differences in lipid levels between the groups; \*p \< 0.05*.

Analysis of Glycerolipids {#S3-2}
-------------------------

Glycerolipid is a class of lipids that account for a high proportion of total lipids in plasma. Structurally glycerolipids contain a glycerol backbone linked to one, two, or three fatty acid chains. The main subclass of glycerolipids in plasma is TG also called triacylglycerol. TG is normally transported in the blood as a constituent of lipoproteins. The two other subclasses in this class are precursors of TG; they are DG and MG. Both are also present in lipoproteins. We analyzed all three subclasses in our cohorts and as expected TG was the most abundant of the three subclasses (Table [1](#T1){ref-type="table"}). TG also had the highest number of lipid species with 1,115 species identified (Table [1](#T1){ref-type="table"}). TG was significantly increased in bvFTD compared to control (Figure [1](#F1){ref-type="fig"}). There was a non-significant increase (*p* = 0.084) in DG in bvFTD compared to control with no significant change in MG.

![Lipids that were significantly altered in behavioral variant frontotemporal dementia. Total relative abundance of lipids following multivariate analyses covarying for age and gender; Data represent mean and SE as error bars, \**p* \< 0.05. TG, triglyceride; PS, phosphatidylserine; PG, phosphatidylglycerol; MGDG, monogalactosyldiacylglycerol; SiE, sitosteryl ester.](fneur-09-00104-g001){#F1}

An analysis of each individual species showed that 97 TG species were significantly increased in bvFTD compared to control (Figure [2](#F2){ref-type="fig"}A; Table [2](#T2){ref-type="table"}), whereas only 10 TG species were significantly increased in AD compared to control (Figure [2](#F2){ref-type="fig"}B; Table [2](#T2){ref-type="table"}). There were also TG species that decreased significantly in bvFTD, but fewer in number than those that increased significantly (Figure [2](#F2){ref-type="fig"}A; Table [2](#T2){ref-type="table"}). A few of the species overlapped between bvFTD and AD. Furthermore, the mean fold change of these species that increased significantly in bvFTD was 0.84, whereas the mean fold change of these species that decreased significantly in FTD was only 0.39. We identified two glycerolipid species that could be potentially used for developing biomarkers for differentiating bvFTD from AD and controls (Table [3](#T3){ref-type="table"}). One is a TG species (CalcMz = 824.77) with 16 carbons in each of the three fatty acid chains, and the other is a DG species (CalcMz = 696.65) with 18 and 22 carbons in each of the two fatty acid chains.

![Triglyceride species that were significantly altered in **(A)** behavioral variant frontotemporal dementia (bvFTD) and **(B)** Alzheimer's disease (AD) compared to control. Each symbol represents a lipid species with different number of carbon atoms in fatty acid chains; red symbols are those that are significantly increased and blue symbols significantly decreased; *p* \< 0.05. The data presented are fold changes on linear scale. Zero represents no change; 0.5 fold change represents 50% increase; and −0.5 represents 50% decrease.](fneur-09-00104-g002){#F2}

###### 

Individual triglyceride species that were significantly altered (*p* \< 0.05) in behavioral variant frontotemporal dementia (bvFTD) and Alzheimer's disease (AD) compared to control.

  Species     CalcMz     C atoms   Fold change   Species    CalcMz     C atoms   Fold change   Species     CalcMz      C atoms   Fold change
  ----------- ---------- --------- ------------- ---------- ---------- --------- ------------- ----------- ----------- --------- -------------
  **bvFTD**                                                                                                                      
                                                                                                                                 
  TG(27:1)    528.4259   27        0.4982        TG(52:1)   878.8171   52        0.2841        TG(55:3)    916.8328    55        0.5622
  TG(32:0)    600.5198   32        −0.5899       TG(52:1)   878.8171   52        0.5901        TG(55:4)    914.8171    55        0.3923
  TG(36:0)    656.5824   36        0.8793        TG(52:1)   878.8171   52        1.4626        TG(55:6)    910.7858    55        0.3078
  TG(36:0)    656.5824   36        −0.4573       TG(52:1)   878.8171   52        1.1662        TG(55:7)    908.7702    55        −0.6356
  TG(36:0)    640.5875   36        0.9205        TG(52:2)   876.8015   52        −0.3672       TG(56:1)    934.8797    56        1.3298
  TG(41:6)    714.5667   41        0.4153        TG(52:2)   876.8015   52        −0.4142       TG(56:12)   895.6810    56        −0.3768
  TG(46:1)    794.7232   46        0.7745        TG(52:2)   876.8015   52        −0.3657       TG(56:3)    930.8484    56        −0.2662
  TG(46:1)    794.7232   46        1.2207        TG(52:2)   876.8015   52        −0.4340       TG(56:3)    930.8484    56        0.4327
  TG(46:2)    792.7076   46        0.9764        TG(52:2)   876.8015   52        −0.5441       TG(56:3)    930.8484    56        0.6351
  TG(46:3)    773.6654   46        1.1936        TG(52:2)   876.8015   52        −0.3999       TG(56:3)    930.8484    56        0.6489
  TG(47:1)    808.7389   47        0.7937        TG(52:2)   876.8015   52        −0.2465       TG(56:4)    911.8062    56        1.2795
  TG(47:1)    808.7389   47        0.7754        TG(52:2)   876.8015   52        0.1849        TG(56:5)    926.8171    56        −0.6279
  TG(47:1)    808.7389   47        0.6329        TG(52:2)   876.8015   52        0.2489        TG(56:6)    924.8015    56        −0.5215
  TG(47:2)    806.7232   47        0.6920        TG(52:2)   876.8015   52        −0.5704       TG(56:6)    924.8015    56        0.7912
  TG(48:0)    824.7702   48        0.6871        TG(52:3)   874.7858   52        −0.2792       TG(57:2)    946.8797    57        0.4328
  TG(48:1)    822.7545   48        0.5545        TG(52:3)   874.7858   52        0.2654        TG(57:8)    934.7858    57        −0.6421
  TG(48:1)    822.7545   48        0.5114        TG(52:3)   874.7858   52        0.2886        TG(58:1)    962.9110    58        0.9877
  TG(48:1)    822.7545   48        1.2236        TG(52:3)   874.7858   52        −0.5628       TG(58:12)   940.7389    58        −0.3962
  TG(48:1)    822.7545   48        1.1809        TG(52:3)   874.7858   52        0.6426        TG(58:2)    960.8954    58        1.1730
  TG(48:1)    822.7545   48        −0.5632       TG(52:3)   874.7858   52        1.3901        TG(58:2)    960.8954    58        0.7577
  TG(48:2)    820.7389   48        0.7358        TG(52:4)   855.7436   52        4.8063        TG(58:7)    950.8171    58        −0.7300
  TG(48:2)    820.7389   48        0.6278        TG(52:5)   870.7545   52        1.1495        TG(58:9)    946.7858    58        −0.4555
  TG(48:3)    818.7232   48        0.9364        TG(52:7)   849.6967   52        0.2657        TG(59:10)   958.7858    59        −0.3153
  TG(48:4)    799.6810   48        0.6024        TG(53:1)   892.8328   53        0.7524        TG(59:11)   956.7702    59        −0.1824
  TG(48:5)    797.6654   48        0.6661        TG(53:2)   890.8171   53        0.9150        TG(59:11)   956.7702    59        −0.2204
  TG(48:6)    795.6497   48        0.9740        TG(53:2)   890.8171   53        0.3567        TG(60:1)    990.9423    60        1.0776
  TG(49:1)    836.7702   49        0.9555        TG(53:2)   890.8171   53        1.1339        TG(60:10)   972.8015    60        −0.3195
  TG(49:2)    834.7545   49        0.5649        TG(53:2)   890.8171   53        −0.4249       TG(60:10)   972.8015    60        −0.4240
  TG(49:2)    834.7545   49        0.6702        TG(53:3)   888.8015   53        0.6572        TG(60:11)   970.7858    60        −0.4395
  TG(49:3)    832.7389   49        0.7762        TG(53:3)   888.8015   53        0.6660        TG(60:11)   970.7858    60        −0.3806
  TG(49:6)    809.6654   49        2.1358        TG(53:3)   888.8015   53        0.3449        TG(60:11)   970.7858    60        −0.4818
  TG(50:1)    850.7858   50        −0.2550       TG(53:3)   888.8015   53        3.2448        TG(60:13)   949.7280    60        −0.5261
  TG(50:1)    850.7858   50        0.3641        TG(53:4)   869.7593   53        1.1373        TG(60:14)   947.7123    60        −0.4243
  TG(50:1)    850.7858   50        0.5101        TG(53:5)   884.7702   53        −0.5024       TG(60:2)    988.9267    60        0.9567
  TG(50:2)    848.7702   50        −0.1614       TG(53:5)   867.7436   53        0.3842        TG(61:12)   982.7858    61        −0.0408
  TG(50:2)    848.7702   50        −0.4823       TG(53:6)   865.7280   53        0.3688        TG(61:2)    1002.9423   61        0.9656
  TG(50:2)    848.7702   50        1.0191        TG(53:7)   880.7389   53        −0.6213       TG(62:11)   998.8171    62        −0.3718
  TG(50:2)    848.7702   50        0.4075        TG(53:8)   878.7232   53        −0.4478       TG(62:11)   998.8171    62        −0.2155
  TG(50:2)    848.7702   50        0.3828        TG(54:1)   906.8484   54        0.9792        TG(62:12)   996.8015    62        −0.5144
  TG(50:2)    848.7702   50        1.0730        TG(54:2)   904.8328   54        −0.3648       TG(62:12)   996.8015    62        −0.4528
  TG(50:2)    848.7702   50        1.1979        TG(54:2)   904.8328   54        −0.4537       TG(62:12)   996.8015    62        −0.3850
  TG(50:3)    846.7545   50        0.7931        TG(54:2)   904.8328   54        −0.3722       TG(62:13)   994.7858    62        −0.3107
  TG(50:3)    846.7545   50        0.3762        TG(54:3)   902.8171   54        −0.2946       TG(62:13)   994.7858    62        −0.2671
  TG(50:6)    823.6810   50        0.3960        TG(54:3)   902.8171   54        0.1926        TG(62:13)   994.7858    62        −0.3061
  TG(51:1)    864.8015   51        1.0157        TG(54:3)   902.8171   54        0.5077        TG(62:15)   973.7280    62        −0.4308
  TG(51:1)    864.8015   51        1.7421        TG(54:3)   902.8171   54        1.5160        TG(64:12)   1024.8328   64        −0.3808
  TG(51:2)    862.7858   51        0.8935        TG(54:3)   902.8171   54        1.7631        TG(64:13)   1022.8171   64        −0.3285
  TG(51:2)    862.7858   51        0.6167        TG(54:4)   900.8015   54        0.5103        TG(64:3)    1042.9736   64        1.1823
  TG(51:3)    860.7702   51        0.5211        TG(54:4)   883.7749   54        0.3293        TG(64:7)    1034.9110   64        −0.3104
  TG(51:3)    860.7702   51        0.4740        TG(54:4)   900.8015   54        1.1544        TG(65:17)   1028.7702   65        −0.2053
  TG(51:3)    860.7702   51        0.5139        TG(54:4)   900.8015   54        0.8247        TG(66:18)   1040.7702   66        −0.0511
  TG(51:6)    854.7232   51        −0.3478       TG(54:5)   881.7593   54        0.7266        TG(66:7)    1062.9423   66        −0.2258
  TG(52:0)    880.8328   52        0.5116        TG(54:5)   882.7909   54        −0.5341       TG(68:7)    1090.9736   68        −0.1900
                                                                                                                                 
  **AD**                                                                                                                         
                                                                                                                                 
  TG(27:1)    528.4259   27        −0.4889       TG(52:2)   876.8015   52        1.2088        TG(55:6)    910.7858    55        0.2013
  TG(32:0)    600.5198   32        −0.4528       TG(52:2)   876.8015   52        0.9103        TG(56:12)   895.6810    56        −0.5378
  TG(36:0)    656.5824   36        −0.4128       TG(52:3)   874.7858   52        1.0580        TG(56:3)    930.8484    56        2.0573
  TG(43:1)    752.6763   43        2.5381        TG(53:5)   884.7702   53        −0.4302       TG(56:5)    926.8171    56        −0.6091
  TG(44:2)    764.6763   44        2.5937        TG(54:3)   902.8171   54        1.7832        TG(56:6)    924.8015    56        −0.5269
  TG(44:5)    741.6028   44        2.5798        TG(54:3)   886.8222   54        −0.4955       TG(57:4)    942.8484    57        −0.6096
  TG(50:1)    850.7858   50        −0.5152       TG(54:5)   882.7909   54        −0.4289       TG(60:3)    986.9110    60        2.8007

###### 

Identification of potential lipid biomarkers.

  Lipid                 Symbol   CalcMz     Formula             Fatty acid       Fold change\*
  --------------------- -------- ---------- ------------------- ---------------- ---------------
  Triglyceride          TG       824.7702   C51 H102 O6 N1      16:0/16:0/16:0   1.69
  Diglyceride           DG       696.6501   C43 H86 O5 N1       18:1/22:0        2.08
  Phosphatidylcholine   PC       734.5694   C40 H81 O8 N1 P1    32:0             0.49
  Phosphatidylserine    PS       850.5604   C47 H81 O10 N1 P1   41:5             0.68
  Sphingomyelin         SM       725.5592   C41 H78 O6 N2 P1    36:4             1.17

*Lipid molecules that were significantly altered in behavioral variant frontotemporal dementia (bvFTD) compared to both Alzheimer's disease and control. CalcMz, calculated mass; fatty acid shows the number of carbon atoms and double bonds in fatty acid chains; fold change indicates the fold difference between bvFTD and control; \**p* \< 0.005*.

Analysis of Phospholipids {#S3-3}
-------------------------

The next class of lipids we investigated was phospholipids. Phospholipids are a major component of all cell membranes. In blood plasma, phospholipids are a major component of all lipoprotein membranes. A typical phospholipid molecule consists of a hydrophilic phosphate head and two lipophilic (hydrophobic) fatty acid chains. Their amphiphilic (both hydrophilic and lipophilic) property allows them to form lipid bilayers in the case of cell membranes and lipid monolayers in the case of lipoprotein membranes. The phosphate group is usually modified with simple organic molecules giving rise to different subclasses. The six major subclasses are PC, PS, PE, PI, PG, and PA. An analysis of total abundance of this class showed that PC was by far the most abundant subclass, followed by PS, PE, PG, PA, and PI (Table [1](#T1){ref-type="table"}). There was a significant decrease in PS compared to both control and AD (Figure [1](#F1){ref-type="fig"}). PG was also significantly decreased in bvFTD compared to control only (Figure [1](#F1){ref-type="fig"}). There were no significant changes in any of other subclasses with a non-significant decrease (*p* = 0.092) in PC in bvFTD compared to control (Table [1](#T1){ref-type="table"}). We also analyzed the level of individual species and have found that 18 PS species were significantly decreased in bvFTD (Figure [3](#F3){ref-type="fig"}A; Table [4](#T4){ref-type="table"}). In contrast, only one PS species was significantly decreased in AD (Figure [3](#F3){ref-type="fig"}B; Table [4](#T4){ref-type="table"}). None of the species overlapped between bvFTD and AD. Likewise, five PG species were significantly decreased in bvFTD and only one was significantly decreased in AD. Similarly, 87 PC species were significantly decreased in bvFTD and only 11 were significantly decreased in AD. We have identified one PS and one PC species that could be potentially used for developing biomarkers for bvFTD (Table [3](#T3){ref-type="table"}).

![Phosphatidylserine species that were significantly altered in **(A)** behavioral variant frontotemporal dementia (bvFTD) and **(B)** Alzheimer's disease (AD) compared to control. Each symbol represents a lipid species with different number of carbon atoms in fatty acid chains; red symbols are those that are significantly increased and blue symbols significantly decreased; *p* \< 0.05. The data presented are fold changes on linear scale. Zero represents no change; 0.5 fold change represents 50% increase; and −0.5 represents 50% decrease.](fneur-09-00104-g003){#F3}

###### 

Individual phosphatidylserine (PS) species that were significantly altered (*p* \< 0.05) in behavioral variant frontotemporal dementia (bvFTD) and Alzheimer's disease (AD) compared to control.

  Species     CalcMz     C atoms   Fold change   Species    CalcMz     C atoms   Fold change   Species     CalcMz     C atoms   Fold change
  ----------- ---------- --------- ------------- ---------- ---------- --------- ------------- ----------- ---------- --------- -------------
  **bvFTD**                                                                                                                     
                                                                                                                                
  PS(35:1)    774.5291   35        −0.7322       PS(41:4)   852.5760   41        −0.6634       PS(43:4)    880.6073   43        0.5540
  PS(39:3)    826.5604   39        −0.3133       PS(41:5)   850.5604   41        −0.7109       PS(45:10)   896.5447   45        −0.2712
  PS(39:4)    824.5447   39        −0.5198       PS(41:5)   850.5604   41        −0.6849       PS(45:6)    904.6073   45        −0.5349
  PS(39:4)    824.5447   39        −0.3506       PS(41:6)   848.5447   41        −0.4904       PS(47:11)   922.5604   47        −0.4057
  PS(39:5)    822.5291   39        −0.4708       PS(41:6)   848.5447   41        −0.5897       PS(48:10)   938.5917   48        −0.3612
  PS(39:5)    822.5291   39        −0.6669       PS(42:6)   848.5811   42        −0.6424                                        
  PS(40:5)    822.5654   40        −0.3915       PS(42:6)   848.5811   42        −0.6019                                        
                                                                                                                                
  **AD**                                                                                                                        
                                                                                                                                
  PS(34:0)    762.5291   34        −0.4638                                                                                      

Analysis of Sphingolipids {#S3-4}
-------------------------

Sphingolipids (also called glycosylceramides) are a class of lipids containing a backbone of So. A basic form of sphingolipid is Cer, which is a precursor to many other sphingolipids, including glucosylceramide and SM. They are a major component of cell membranes and play a role in cell signaling. In blood plasma, they are associated with lipoproteins. The major subclasses identified in our lipidomics analysis were Cer, monoglycosylceramide (CerG1), ceramide phosphate (CerP), SM, So, and sphingosine phosphate (SoP). There were no significant changes in the total abundance of any of the sphingolipid subclasses in bvFTD compared to control (Table [1](#T1){ref-type="table"}). However, we have identified one SM species that was significantly increased in bvFTD compared to control and AD. This species could potentially serve as a biomarker for bvFTD (Table [3](#T3){ref-type="table"}).

Analysis of Sterols {#S3-5}
-------------------

Cholesterol is the most abundant sterol in plasma. Two sterols were identified in our lipidomics analysis, ChE and zymosteryl ester (ZyE). ChE is composed of a cholesterol molecule with a single fatty acid chain. ChE is the storage form of cholesterol, and in blood plasma, the majority of cholesterol transported by lipoproteins are in this form. ZyE is derived from zymosterol, which is an intermediate in cholesterol biosynthesis. In terms of total abundance, there were no significant changes in either ChE or ZyE in bvFTD compared to control (Table [1](#T1){ref-type="table"}). We have identified 44 ChE and 22 ZyE species in this lipid class (Table [1](#T1){ref-type="table"}); however, none of them were significantly altered (i.e., *p* \< 0.005) to be considered as a potential biomarker.

Analysis of Dietary (Plant) Lipids {#S3-6}
----------------------------------

In our lipidomics analysis, we have identified a number of dietary lipids. These were monogalactosyldiacylglycerol (MGDG), stigmasteryl ester (StE), sitosteryl ester (SiE), and wax ester (WE). These lipids are normally derived from food matter originating from plants or marine creatures. The plant lipids (MGDG, StE, and SiE) are not synthesized in humans but are derived entirely from diet. MGDG is a component of the thylakoid membrane of plant chloroplasts and as such it is one of the most abundant lipids in nature. It is consumed by humans as a part of vegetable diet. SiE is a major dietary plant sterol (also called phytosterol). It is found in vegetable oils, nuts, and vegetables. StE is also a phytosterol and is found in vegetables, legumes, nuts, seeds, and a number of medicinal herbs. WE is commonly found in arthropods (e.g., shrimps), shellfish, certain fish species, as well as in whole grain cereals, seeds, and nuts. The total abundance of MGDG was significantly decreased in bvFTD compared to controls and AD (Figure [1](#F1){ref-type="fig"}). Likewise, the total abundance of SiE was significantly decreased in bvFTD compared to controls (Figure [1](#F1){ref-type="fig"}). SiE was also significantly decreased in AD compared to control (Figure [1](#F1){ref-type="fig"}). The total abundances of StE and WE were unaltered in both bvFTD and AD (Table [1](#T1){ref-type="table"}).

Correlations {#S3-7}
------------

Pearson correlation was used to test for any association between lipids. TG was positively correlated with its two precursors DG (*r* = 0.844, *p* = 3.8 × 10^−15^) and MG (*r* = 0.611, *p* = 1 × 10^−6^) as expected, positively validating our lipidomics data. TG was negatively correlated with ChE (*r* = −0.405, *p* = 0.003) and ZyE (*r* = −0.501, *p* = 0.0002). All six subclasses of the phospholipid class correlated strongly with each other (all six). For example, the correlation between PC and PE was *r* = 0.783, *p* = 6.8 × 10^−12^, and between PS and PI was *r* = 0.719, *p* = 1.9 × 10^−9^. The correlation among phospholipid subclasses is expected to be positive since their distribution in lipoprotein membranes is normally constant. All phospholipids correlated positively with sphingolipids Cer, SM, and So, which are also components of lipoprotein membranes. PC was the only phospholipid that correlated with ChE (*r* = 0.441, *p* = 0.001). All sphingolipids correlated positively with each other as expected. For example, the correlation between Cer and SM was *r* = 0.654, *p* = 1.5 × 10^−7^, and between SM and So was *r* = 0.685, *p* = 2.2 × 10^−8^. SM was positively correlated with ChE (*r* = 0.516, *p* = 9.1 × 10^−5^). ChE was strongly correlated with its precursor ZyE (*r* = 0.813, *p* = 2.5 × 10^−13^) as expected, once again positively validating our lipidomics data. Of interest, the plant lipid MGDG correlated positively with all the phospholipids, in particular PS (*r* = 0.669, *p* = 5.9 × 10^−8^) and PI (*r* = 0.697, *p* = 9.7 × 10^−9^). Also of interest, all of the esters (ChE, ZyE, StE, SiE, and WE) correlated positively with each other. For example, the correlation between ChE and WE was *r* = 0.844, *p* = 3.9 × 10^−15^.

Discussion {#S4}
==========

Lipidomics has been increasingly used to study lipid dysfunction and has provided invaluable data in understanding disease pathogenesis of a number of diseases. One clear and consistent finding from all studies is the vast array and complexity of lipid species present in human plasma. This has provided the scope to utilize lipidomics in disease classification and biomarker development. As of present, lipidomics of bvFTD has not been reported. Our study therefore represents the first lipidomics analysis of blood samples of patients with bvFTD. Our aim was to establish a differentiating plasma lipid profile for bvFTD and to uncover changes in lipid levels associated with this disease. Identification of altered lipid species in bvFTD would allow development of a potential objective biomarker for bvFTD. Furthermore, analysis of lipid changes in bvFTD would facilitate our understanding of the metabolic changes that are evident in bvFTD patients and of the lipid loss that is directly associated with neurodegeneration.

The first class of lipids we analyzed was glycerolipids; subclasses TG, DG, and MG. Emerging evidence indicates that hypertriglyceridemia is a characteristic of bvFTD, and a recent measurement of TG in bvFTD (by an indirect enzymatic method) showed that it was significantly increased (based on our statistical analysis) compared to controls ([@B18]). Consistent with this, we have shown that TG was significantly increased in bvFTD. There are a number of factors that can contribute toward hypertriglyceridemia and these include uncontrolled diabetes mellitus, obesity, sedentary lifestyle, and genetic determinants. We know that bvFTD patients have eating disorder, i.e., binge eating and increased intake of sweet foods ([@B15], [@B22]), and this is likely to have contributed toward hypertriglyceridemia. This is supported by the fact that bvFTD patients have significantly higher blood insulin levels compared to healthy controls ([@B23]). Elevated TG levels, as well as DG and MG levels, and elevated insulin levels suggest a state of insulin resistance. Diets high in refined carbohydrates (sugar) are known to increase TG levels. This correlation is stronger for those with high BMI (≥ 28) ([@B24]). The average BMI for bvFTD is 29.65 ([@B17]), and therefore, bvFTD patients have a higher risk of developing carbohydrate-induced hypertriglyceridemia. It is interesting to note that heavy alcohol consumption can also induce hypertriglyceridemia ([@B25], [@B26]); increased alcohol consumption is also a characteristic of bvFTD. Unabated hypertriglyceridemia, accompanied by low HDL-cholesterol, would increase the risk of coronary heart disease. There is also evidence that hypertriglyceridemia with low HDL-cholesterol is associated with an increased risk of developing mild cognitive impairment ([@B27], [@B28]). Further research is required to understand the relationship between hypertriglyceridemia, bvFTD, and cognitive impairment.

Previous lipidomics analyses (not in bvFTD) showed that a considerable number of TG and DG species were closely associated with dyslipidemia, and TG 50:2, 52:2, 52:3, and 52:4 were the most abundant species ([@B29]). In a twin study, consisting of 14 pairs of young-adult monozygotic twins discordant for obesity, several TG species correlated significantly with BMI and subcutaneous fat measurement ([@B30]). A prominent TG that was identified from the study was TG 56:4 with the suggestion that this species may serve as a potential biomarker for the detection of acquired obesity. In our lipidomics analysis, TG 56:4 was the second most significantly increased TG species with a *p* value of 0.0006.

Phospholipids are abundant in blood plasma as a major component of lipoprotein membranes. We have identified six subclasses of phospholipids. Our data showed significant decreases (based on our statistical analysis) in the total abundance of PS and PG in bvFTD compared to control and an overall non-significant trend for a decrease in other phospholipids in bvFTD. The total abundance of PS was also significantly decreased in bvFTD compared to AD; PS was the only lipid subclass in all non-plant lipid subclasses measured that was significantly altered in bvFTD compared to both control and AD. A body of evidence suggests that decreases in PS level in the brain could be associated with cognitive decline ([@B31], [@B32]). As a major component of neuronal membrane and myelin, PS is essential for their formation and maintenance ([@B33], [@B34]). Studies with old rats have shown that oral intake of PS increased neurotransmission signals ([@B35]--[@B37]) and improved learning and memory ([@B38]--[@B40]). PS is absorbed into the bloodstream following ingestion and readily crosses the blood--brain barrier ([@B41], [@B42]).

A comparison of individual species showed numerous PS, PG, and PC species that were significantly decreased in bvFTD. In contrast, very few species were altered in AD. PC is the most abundant phospholipid in all lipoproteins, especially in HDL. As expected, it was by far the most abundant phospholipid in our plasma samples. Furthermore, the PC subclass contained by far the most number of putative species (i.e., 1,062). Its abundance and structural diversity suggest critical involvement in physiological processes. In fact, PC has an important and unique function, in that it is the only phospholipid which is currently known to be required for lipoprotein assembly and secretion ([@B43]). An interesting observation from our study was that reduced levels of phospholipids in bvFTD (indicating reduced numbers of HDL) corroborates the previous finding that HDL-cholesterol is reduced in bvFTD ([@B18]). In support, there was a positive correlation between PC and ChE. These results when put together suggest an increased risk of hypoalphalipoproteinemia in bvFTD.

The levels of sphingolipids were largely unaltered in bvFTD and AD cohorts. A previous study reported elevated plasma levels in AD, although these changes were observed in early AD or mild cognitive impairment ([@B44]). Earlier lipidomics analyses of healthy controls have identified \>200 sphingolipid species ([@B45], [@B46]); we have identified 329 sphingolipids species with 229 SM species alone. The overall levels of ChE (as well as ZyE) were unaltered in bvFTD or AD. This result was in accordance with a previous study, in which total cholesterol (measured by an enzymatic colorimetric assay), was unaltered in bvFTD ([@B18]).

In our lipidomics analysis, we also identified three groups of dietary lipids (MGDG, StE, and SiE) originating from plants. These lipids are not synthesized in humans but are derived entirely from diet, and therefore, they can be used as indicators of what food people ate. Both MGDG and SiE were significantly decreased in bvFTD (both unchanged in AD). This suggests that the patients with bvFTD consume reduced amounts of plant matter (i.e., vegetables and fruits) compared to controls. Another plant sterol, StE, was unaltered in bvFTD. The level of WE (e.g., shrimps and shellfish) was also unaltered in bvFTD. Therefore, the consumption of only certain food categories is altered in bvFTD.

A number of protocols/strategies have been developed for lipidomics of human plasma ([@B47]), and we have used one of the most common and efficient strategies---a single phase extraction method followed by liquid chromatography, ESI, and tandem mass spectrometry. This strategy allows the accurate measurement of literally hundreds, if not thousands, of different lipid species in a single biological sample. A watershed for lipidomics has been the development of ESI in mass spectrometry. ESI is a technique to generate ions from molecules. The advantage of ESI over other techniques is that very little fragmentation of molecules occurs during the ionization process, although this is still a limitation. The structural diversity is particularly apparent with TG and PC, for which we have identified 1,115 and 1,062 distinct molecular species, respectively. Recent improvements in mass spectrometry in lipids have allowed detection and quantification of individual molecular species. To determine the efficiency of recovery of lipids, our plasma samples were spiked with a number of ISTDs of known quantity. All ISTDs achieved expected high recovery rates, i.e., \>98%. This indicated that the extraction method, based on the method of Bligh and Dyer ([@B20]), was thorough and resulted in a comprehensive recovery of lipids. Our choice for this extraction method was based on a previous study, in which five different extraction methods were tested for blood plasma ([@B48]). The Bligh and Dyer method was considered the best in terms of coverage and reproducibility across a variety of lipid classes, i.e., "broad-based" lipidomics. Nevertheless, limitations still exist because not all (100%) of lipids present in a given sample can be analyzed. Further limitations lie in the statistical approach we used to analyze the lipidomics dataset. An empirical Bayesian approach is an alternative that would increase power and reduce false positives.

Like transcriptomics and proteomics, lipidomics gives the opportunity to investigate biological changes at a systems level to allow the identification and measurement of distinct metabolites that change with different disease states. Limitations and questions still remain as to why there are so many species of lipids in blood and what are their functions. This conundrum is somewhat similar to the enormous stretches of non-coding DNA in the genome that was once called "junk DNA," these are now known to play important roles in gene regulation and epigenetics.

We have demonstrated that significant lipid changes occur in the blood as a consequence of bvFTD. We have identified a number of individual lipid species from each lipid class that could potentially be used for developing biomarkers for bvFTD. Future work would involve developing a combination of lipid species that could serve as a reproducible objective lipid signature to differentiate bvFTD from AD and controls, in particular at preclinical and various stages of disease progression. Our lipidomics analysis has not only identified lipids that change in bvFTD, it has also provided data that could be utilized to identify biosynthetic enzymes and metabolic pathways that are altered in bvFTD. In conclusion, our study has provided new insights into an unrecognized perturbed pathology in bvFTD, providing evidence in support of considerable lipid dysregulation in bvFTD.
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